Cerebral proliferative angiopathy is a rare diffuse cerebral vascular malformation distinct from classical arteriovenous malformations. It is characterized by abnormal arteriovenous channels intermingled with normal brain parenchyma, absence of a compact nidus or dominant feeders, and clinical presentations including focal deficits, headache, seizures, ischemia, and rarely hemorrhage.
Ask a research question about Cerebral Proliferative Angiopathy. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Cerebral Proliferative Angiopathy
creation_date: "2026-05-05T15:37:54Z"
updated_date: "2026-05-05T16:34:00Z"
description: >-
Cerebral proliferative angiopathy is a rare diffuse cerebral vascular
malformation distinct from classical arteriovenous malformations. It is
characterized by abnormal arteriovenous channels intermingled with normal
brain parenchyma, absence of a compact nidus or dominant feeders, and clinical
presentations including focal deficits, headache, seizures, ischemia, and
rarely hemorrhage.
category: Complex
disease_term:
preferred_term: cerebral proliferative angiopathy
term:
id: MONDO:0979258
label: cerebral proliferative angiopathy
parents:
- Vascular disorder
synonyms:
- CPA
pathophysiology:
- name: Chronic perinidal ischemia and oligemia
description: >-
CPA is hypothesized to arise from reduced perinidal perfusion and chronic
cortical ischemia, which promotes diffuse angiogenesis and recruitment of
abnormal arteriovenous channels.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: response to hypoxia
modifier: INCREASED
term:
id: GO:0001666
label: response to hypoxia
evidence:
- reference: PMID:18239181
reference_title: "Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral AVMs."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
The diffuse angiogenetic activity is presumably related to reduced perinidal perfusion and subsequent chronic cortical ischemia.
explanation: The field-defining cohort links reduced perinidal perfusion and chronic cortical ischemia to diffuse angiogenetic activity in CPA.
downstream:
- target: Diffuse proliferative cerebral arteriovenous malformation
description: Chronic ischemia and oligemia are proposed to drive diffuse proliferative vascular remodeling.
- name: Diffuse proliferative cerebral arteriovenous malformation
description: >-
CPA has a diffuse angioarchitecture with intermingled brain parenchyma and
no compact nidus, distinguishing it from classic arteriovenous malformation.
The malformation alters local cerebral circulation and can involve eloquent
brain regions.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: angiogenesis
modifier: INCREASED
term:
id: GO:0001525
label: angiogenesis
evidence:
- reference: PMID:39833329
reference_title: A potential VEGF-driven hypothesis of calvarial centripetal proliferation in cerebral proliferative angiopathy.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cerebral proliferative angiopathy (CPA) is a rare subtype of cerebral arteriovenous malformation, characterized by unique angiographic features and clinical presentations.
explanation: This multicenter cohort defines CPA as a rare arteriovenous malformation subtype with distinctive angiographic and clinical features.
- reference: PMID:37701260
reference_title: Recurrent Intraventricular Haemorrhage in Cerebral Proliferative Angiopathy - A Case Report and Review of the Literature.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Angioarchitectural workup revealed intermingled brain parenchyma between vascular spaces, absence of dominant feeders and a clear nidus consistent with CPA.
explanation: This directly supports the diffuse, parenchyma-intermixed architecture of CPA.
downstream:
- target: Altered cerebral perfusion and ischemic symptoms
description: Diffuse vascular shunting and hemodynamic delay can disturb cerebral blood flow.
- target: VEGF-associated calvarial centripetal proliferation hypothesis
description: Diffuse proangiogenic CPA biology may promote local VEGF-associated adjacent tissue remodeling.
- name: Altered cerebral perfusion and ischemic symptoms
description: >-
CPA can alter cerebral hemodynamics, producing focal deficits, headache, and
seizures; pediatric cases often present with ischemia and diffuse
eloquent-intermixed vasculature.
biological_processes:
- preferred_term: response to hypoxia
modifier: ABNORMAL
term:
id: GO:0001666
label: response to hypoxia
evidence:
- reference: PMID:41652190
reference_title: "Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Pediatric CPA often manifests with ischemia and diffuse, eloquent-intermixed vasculature.
explanation: The pediatric systematic review supports ischemia and diffuse eloquent vasculature as central clinical-mechanistic features.
- reference: PMID:41573183
reference_title: Evaluating Vascular Hemodynamics in Cerebral Proliferative Angiopathy Using Advanced Arterial Spin Labeling MRI.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cerebral proliferative angiopathy (CPA) is a rare vascular disorder that affects normal blood circulation in the brain.
explanation: This imaging report supports abnormal cerebral blood circulation as a CPA feature.
- name: VEGF-associated calvarial centripetal proliferation hypothesis
description: >-
Some patients have calvarial thickening adjacent to CPA. A proangiogenic
mechanism involving elevated VEGF has been proposed as a hypothesis linking
CPA biology to surrounding tissue remodeling.
cell_types:
- preferred_term: endothelial cell
term:
id: CL:0000115
label: endothelial cell
biological_processes:
- preferred_term: angiogenesis
modifier: INCREASED
term:
id: GO:0001525
label: angiogenesis
evidence:
- reference: PMID:39833329
reference_title: A potential VEGF-driven hypothesis of calvarial centripetal proliferation in cerebral proliferative angiopathy.
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
We hypothesized that this may be related to elevated vascular endothelial growth factor levels due to the proangiogenic nature of CPA.
explanation: The abstract presents VEGF involvement as a hypothesis rather than a proven causal mechanism.
phenotypes:
- category: Neurologic
name: Cerebral vascular malformation
diagnostic: true
description: CPA is a diffuse cerebral vascular malformation with characteristic angiographic architecture.
phenotype_term:
preferred_term: Cerebral vascular malformation
term:
id: HP:0100026
label: Arteriovenous malformation
evidence:
- reference: PMID:37701260
reference_title: Recurrent Intraventricular Haemorrhage in Cerebral Proliferative Angiopathy - A Case Report and Review of the Literature.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cerebral proliferative angiopathy (CPA) is an entity distinct from that of classical arteriovenous malformations.
explanation: This supports CPA as a distinct cerebral vascular malformation entity.
- category: Neurologic
name: Focal neurologic deficits
description: Focal deficits are a common presentation in pediatric CPA case aggregation.
phenotype_term:
preferred_term: Focal neurologic deficits
evidence:
- reference: PMID:41652190
reference_title: "Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Common symptoms were focal deficits (n = 17), headache (n = 15), and seizures (n = 6).
explanation: The systematic review identifies focal deficits as common in pediatric CPA.
- category: Neurologic
name: Headache
description: Headache is a common clinical presentation.
phenotype_term:
preferred_term: Headache
term:
id: HP:0002315
label: Headache
evidence:
- reference: PMID:41652190
reference_title: "Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Common symptoms were focal deficits (n = 17), headache (n = 15), and seizures (n = 6).
explanation: The systematic review identifies headache as a common CPA symptom.
- category: Neurologic
name: Seizure
description: Seizures may occur as part of the CPA presentation.
phenotype_term:
preferred_term: Seizure
term:
id: HP:0001250
label: Seizure
evidence:
- reference: PMID:41652190
reference_title: "Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Common symptoms were focal deficits (n = 17), headache (n = 15), and seizures (n = 6).
explanation: The systematic review identifies seizures among pediatric CPA presentations.
- category: Neurologic
name: Intracranial hemorrhage
description: Hemorrhage appears uncommon but may recur when it occurs.
phenotype_term:
preferred_term: Intracranial hemorrhage
term:
id: HP:0002170
label: Intracranial hemorrhage
evidence:
- reference: PMID:37701260
reference_title: Recurrent Intraventricular Haemorrhage in Cerebral Proliferative Angiopathy - A Case Report and Review of the Literature.
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Given our case and review of the literature it is apparent that CPA has a high risk of re-hemorrhage in the rare event that hemorrhage does occur.
explanation: This supports hemorrhage as a rare but clinically important CPA complication.
- category: Neurologic
name: Transient ischemic attack
description: TIA or stroke-like symptoms are a common CPA presentation in systematic review.
phenotype_term:
preferred_term: Transient ischemic attack
term:
id: HP:0002326
label: Transient ischemic attack
evidence:
- reference: PMID:32206904
reference_title: "The Current Clinical Features, Management, and Outcomes of Patients with Cerebral Proliferative Angiopathy: A Systematic Review."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
old) and female (60.0%) presenting with headaches (44.9%), seizures (37.1%), or transient ischemic attacks (33.7%).
explanation: The systematic review quantifies transient ischemic attacks in about one-third of CPA cases.
histopathology:
- name: Intermingled normal brain parenchyma
description: Normal brain tissue is interspersed among abnormal vascular channels, distinguishing CPA from compact-nidus AVMs and increasing treatment risk.
diagnostic: true
evidence:
- reference: PMID:18239181
reference_title: "Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral AVMs."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
On cross-sectional imaging, CPA demonstrated as a diffuse network of densely enhancing vascular spaces with intermingled normal brain parenchyma.
explanation: The field-defining paper identifies normal parenchyma intermingled with abnormal vessels as a defining feature.
diagnosis:
- name: Cerebral angiographic and hemodynamic imaging
description: >-
MRI, CT, catheter angiography, and perfusion-oriented methods such as
arterial spin labeling help define CPA architecture, eloquent parenchymal
intermingling, perfusion compromise, and treatment candidacy.
diagnosis_term:
preferred_term: MRI of the brain
term:
id: MAXO:0000427
label: MRI of the brain
results: Imaging may show diffuse abnormal vessels without a compact nidus and with altered cerebral blood flow.
evidence:
- reference: PMID:41573183
reference_title: Evaluating Vascular Hemodynamics in Cerebral Proliferative Angiopathy Using Advanced Arterial Spin Labeling MRI.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Arterial spin labeling (ASL) is a noninvasive magnetic resonance technique that allows quantitative assessments of cerebral blood flow.
explanation: This supports ASL MRI as a hemodynamic imaging method for CPA assessment.
- name: Digital subtraction angiography
description: DSA/catheter angiography defines the diffuse CPA angioarchitecture, small shunting volume, progressive arterial stenoses, and absence of flow-related aneurysms.
results: Angiography shows diffuse vascular network with intermingled normal brain, no compact nidus, and characteristic hemodynamic findings.
evidence:
- reference: PMID:18239181
reference_title: "Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral AVMs."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
CPA may be regarded as a separate clinical entity different to "classical" cerebral AVMs, because normal brain is interspersed with the abnormal vascular channels increasing the risk of neurological deficit in aggressive treatments, which in the light of the natural history does not seem to be indicated.
explanation: The angiographic cohort supports DSA-based recognition of CPA as distinct from classic AVM.
treatments:
- name: Indirect cerebral revascularization
description: >-
For symptomatic children with hypoperfusion, pial synangiosis or related
indirect bypass strategies may be considered to improve perfusion while
avoiding aggressive nidus-directed AVM treatment.
treatment_term:
preferred_term: surgical procedure on cardiovascular system
term:
id: MAXO:0025001
label: surgical procedure on cardiovascular system
evidence:
- reference: PMID:41652190
reference_title: "Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In symptomatic children with hypoperfusion, indirect revascularization is a reasonable strategy to enhance perfusion and reduce recurrent ischemic events.
explanation: The pediatric review directly supports indirect revascularization for symptomatic hypoperfused CPA.
- reference: PMID:41573183
reference_title: Evaluating Vascular Hemodynamics in Cerebral Proliferative Angiopathy Using Advanced Arterial Spin Labeling MRI.
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Our quantitative results indicated that, in regions affected by CPA, cerebral blood flow increased by at least 14% and arterial transit time decreased by 9.4% after bypass surgery.
explanation: This single-patient imaging report supports hemodynamic improvement after bypass surgery.
- name: Targeted endovascular embolization
description: >-
Partial or targeted embolization may be used in selected CPA cases, although
conservative management remains common and evidence is limited.
treatment_term:
preferred_term: endovascular embolization
term:
id: NCIT:C49236
label: Therapeutic Procedure
evidence:
- reference: PMID:32206904
reference_title: "The Current Clinical Features, Management, and Outcomes of Patients with Cerebral Proliferative Angiopathy: A Systematic Review."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
Most patients were treated conservatively (54.4%), followed by endovascular (34.2%).
explanation: The systematic review supports endovascular treatment as a common active intervention, but does not establish superiority.
- reference: PMID:32206904
reference_title: "The Current Clinical Features, Management, and Outcomes of Patients with Cerebral Proliferative Angiopathy: A Systematic Review."
supports: PARTIAL
evidence_source: HUMAN_CLINICAL
snippet: >-
CONCLUSIONS: Conservative and endovascular treatments seem adequate interventions, despite limited evidence.
explanation: The review frames endovascular treatment as adequate but evidence-limited.
review_notes: >-
The reviewer-suggested HP:0007350 was not used for focal neurologic deficits
because the local HPO lookup labels HP:0007350 as "Upper limb hyperreflexia";
additional local HPO searches for focal neurologic/neurological deficit did
not identify a suitable specific term, so the overly broad HP:0000707 term was
removed pending an HPO NTR. The reviewer-suggested MAXO:0000508 was not used
for endovascular embolization because local MAXO labels MAXO:0000508 as
"liquid ventilation"; the page uses generic NCIT:C49236 until a validated
embolization procedure term is available. Propranolol and cilostazol were not
added because the fetched caches did not include validator-backed evidence for
those anecdotal emerging treatments.
CPA is a rare, AVM-like cerebrovascular entity that differs from “classical” brain arteriovenous malformations (bAVMs) in angioarchitecture, clinical presentation, natural history, and treatment implications (lasjaunias2008cerebralproliferativeangiopathy pages 1-2, lasjaunias2008cerebralproliferativeangiopathy pages 2-4). In the foundational Stroke cohort, CPA is described on cross-sectional imaging as “a diffuse network of densely enhancing vascular spaces with intermingled normal brain parenchyma” and angiographically by non-focal angiogenetic activity with numerous small feeders/drainers rather than a compact nidus with high-flow shunting (lasjaunias2008cerebralproliferativeangiopathy pages 2-4, lasjaunias2008cerebralproliferativeangiopathy pages 1-2).
Older or alternative labels used for lesions now considered CPA include: - “Diffuse nidus(-type) AVM” (tiwari2020cerebralproliferativeangiopathy pages 1-3, tiwari2020cerebralproliferativeangiopathy pages 3-4) - “Holohemispheric giant AVM” / “holohemispheric giant cerebral arterio-venous malformation” (yamaki2020thecurrentclinical pages 1-3, lasjaunias2008cerebralproliferativeangiopathy pages 6-7)
Within the retrieved and read sources, no explicit mapping codes (OMIM/Orphanet/ICD/MeSH/MONDO) were provided in text (yamaki2020thecurrentclinical pages 1-3, tiwari2020cerebralproliferativeangiopathy pages 1-3, lasjaunias2008cerebralproliferativeangiopathy pages 1-2). Therefore, this report cannot safely supply specific code identifiers without introducing uncited assumptions.
Evidence is primarily from: - Aggregated disease-level resources: systematic reviews and case series syntheses (e.g., pooled 95 cases) (yamaki2020thecurrentclinical pages 3-4, hess2022cerebralproliferativeangiopathy pages 3-4). - Single-center cohorts / databanks: the Lasjaunias et al. cohort (49 CPA cases identified within an AVM databank) (lasjaunias2008cerebralproliferativeangiopathy pages 2-4). - Individual case reports: especially for emerging diagnostic and therapeutic approaches (2023–2024) (jongaliem2023useofbetablocker pages 1-2, gautam2024thetreatmentof pages 2-4).
No established single-gene cause, inherited syndrome, or somatic mutation driver was identified in the accessed literature. Instead, CPA is repeatedly framed as a hemodynamic/angiogenic disorder, hypothesized to arise from chronic regional hypoperfusion (perinidal oligemia/ischemia) leading to diffuse angiogenesis (lasjaunias2008cerebralproliferativeangiopathy pages 6-7, yamaki2020thecurrentclinical pages 1-3).
Robust epidemiologic risk-factor data (e.g., hypertension, smoking, etc.) were not identified in the accessed evidence base; the available literature is dominated by case reports/series and imaging-characterization studies (yamaki2020thecurrentclinical pages 3-4, hess2022cerebralproliferativeangiopathy pages 3-4). Demographic associations (young age, female predominance) are described (see Epidemiology below) but should be treated as descriptive rather than causal (lasjaunias2008cerebralproliferativeangiopathy pages 2-4, yamaki2020thecurrentclinical pages 3-4).
No protective genetic or environmental factors were reported in the accessed literature.
No gene–environment interactions were reported in the accessed literature.
From Lasjaunias et al. (49 cases): seizures 45%, headaches 41%, TIAs/stroke-like symptoms 16%, hemorrhage 12% (lasjaunias2008cerebralproliferativeangiopathy pages 2-4). From a 2020 systematic review (95 cases): headache 44.9%, seizures 37.1%, transient ischemic attacks 33.7%, hemorrhage 18.0% (yamaki2020thecurrentclinical pages 3-4).
Pediatric phenotype (aggregate of 29 cases): focal deficits (n=17), headache (n=15), seizures (n=6) (moskalik2026cerebralproliferativeangiopathy pages 1-3).
(terms suggested for knowledge-base structuring; not claims of asserted ontology mapping) - Headache (HP:0002315) - Seizures (HP:0001250) - Transient ischemic attack (HP:0002326) - Hemiparesis (HP:0001269) - Aphasia (HP:0002381) - Intracranial hemorrhage (HP:0002170) / Intraventricular hemorrhage (HP:0002133)
Disabling headaches and medically refractory seizures are emphasized as reasons patients seek care and as treatment drivers, reflecting substantial functional burden (lasjaunias2008cerebralproliferativeangiopathy pages 1-2, jongaliem2023useofbetablocker pages 1-2).
No validated causal genes were identified in the accessed CPA literature (yamaki2020thecurrentclinical pages 1-3, lasjaunias2008cerebralproliferativeangiopathy pages 6-7).
Not established for CPA in the accessed sources.
Not reported in the accessed sources.
CPA is repeatedly linked to angiogenesis driven by chronic hypoperfusion/oligemia (lasjaunias2008cerebralproliferativeangiopathy pages 6-7, jongaliem2023useofbetablocker pages 2-4). A 2023 propranolol case report argues for an anti-VEGF/anti-proliferative rationale, stating propranolol is a “VEGF inhibitory agent” and hypothesizing “Propranolol may have an antiproliferative effect on CPA” (jongaliem2023useofbetablocker pages 1-2).
No specific environmental exposures, toxins, lifestyle factors, or infectious triggers were reported in the accessed CPA literature.
Chronic regional hypoperfusion (oligemia/ischemia) → reactive/diffuse angiogenesis (including transdural supply and recruitment of multiple small-caliber vessels) → diffuse intraparenchymal vascular network with intermingled normal brain → clinical syndromes dominated by seizures/headache/ischemic deficits rather than primary hemorrhage (lasjaunias2008cerebralproliferativeangiopathy pages 1-2, lasjaunias2008cerebralproliferativeangiopathy pages 6-7, tiwari2020cerebralproliferativeangiopathy pages 3-4).
Key supportive observations include perfusion MRI patterns: CPA shows increased blood volume with prolonged mean transit time and broader hemispheric hypoperfusion compared with classical AVMs (lasjaunias2008cerebralproliferativeangiopathy pages 6-7).
CPA differs from classic AVM histology by preservation of neural tissue within the lesion; pathology shows vascular wall abnormalities and “normal appearing neural tissue intermingled between these vascular channels” (lasjaunias2008cerebralproliferativeangiopathy pages 4-6).
Lesions are often large and may span lobes/hemisphere; in one pooled review, hemispheric extension was reported in 73.0% (yamaki2020thecurrentclinical pages 3-4). Watershed-zone predominance (70.6%) supports a hypoperfusion-linked distribution (yamaki2020thecurrentclinical pages 3-4).
CPA is usually recognized in young patients, often after neurologic symptoms (seizures, headache, TIAs) rather than hemorrhage (lasjaunias2008cerebralproliferativeangiopathy pages 2-4, yamaki2020thecurrentclinical pages 3-4).
A 2023 pediatric case report described diagnosis of CPA five years after intraventricular hemorrhage and an initially negative catheter angiogram, interpreted as supportive of new-vessel formation/angiogenesis as part of disease evolution (singfer2023cerebralproliferativeangiopathy pages 1-4).
CPA is a minority subset among lesions labeled AVM in major series: - Lasjaunias et al.: 49/1434 (3.4%) of AVM databank cases met CPA criteria (lasjaunias2008cerebralproliferativeangiopathy pages 2-4).
No inheritance pattern has been established in the accessed evidence base (yamaki2020thecurrentclinical pages 1-3, lasjaunias2008cerebralproliferativeangiopathy pages 6-7).
Digital subtraction angiography (DSA) is emphasized as the diagnostic reference standard for angioarchitecture (tiwari2020cerebralproliferativeangiopathy pages 3-4, yamaki2020thecurrentclinical pages 1-3).
Key diagnostic imaging features include: - Diffuse vascular network with intermingled normal brain parenchyma (lasjaunias2008cerebralproliferativeangiopathy pages 2-4, singfer2023cerebralproliferativeangiopathy pages 1-4). - Discrepancy between large lesion size and small shunting volume (lasjaunias2008cerebralproliferativeangiopathy pages 1-2). - No dominant arterial feeder, many small feeders; small draining veins relative to lesion (lasjaunias2008cerebralproliferativeangiopathy pages 1-2, lasjaunias2008cerebralproliferativeangiopathy pages 4-6). - Transdural supply and proximal feeder stenoses (lasjaunias2008cerebralproliferativeangiopathy pages 2-4, yamaki2020thecurrentclinical pages 3-4).
Perfusion/functional hemodynamic testing may support a steal/hypoperfusion mechanism. - A 2024 case report used CT perfusion with acetazolamide challenge to attribute aphasia to steal physiology (gautam2024thetreatmentof pages 1-2, gautam2024thetreatmentof pages 2-4).
Commonly discussed differentials include: - Classic brain AVM (compact nidus, higher hemorrhagic presentation proportion) (yamaki2020thecurrentclinical pages 3-4, lasjaunias2008cerebralproliferativeangiopathy pages 1-2). - Moyamoya disease / moyamoya-like vasculopathies (noted as differential in case literature) (jongaliem2023useofbetablocker pages 1-2).
A 2023 case report provides representative MRI and DSA figures showing a diffuse vascular network with persistent opacification into late arterial/early venous phases and no dominant feeders (singfer2023cerebralproliferativeangiopathy media 68b06269, singfer2023cerebralproliferativeangiopathy media 94c84d95).
CPA generally presents with hemorrhage less often than classical AVMs, but recurrence risk after hemorrhage may be high. - Lasjaunias cohort: hemorrhage at presentation 12% (6/49); among those with hemorrhage, recurrent bleeding reported in 67%, with one death (lasjaunias2008cerebralproliferativeangiopathy pages 2-4). - Systematic review: hemorrhage in 18% and reported rebleeding up to 67% in some series (yamaki2020thecurrentclinical pages 3-4).
Because normal brain tissue is interspersed with abnormal vessels, aggressive curative therapies used for compact AVMs may cause unacceptable neurologic injury. Lasjaunias et al. explicitly caution that “normal brain is interspersed with the abnormal vascular channels increasing the risk of neurological deficit in aggressive treatments,” and given “low risk of hemorrhage,” aggressive treatment is often not indicated (lasjaunias2008cerebralproliferativeangiopathy pages 1-2).
From Yamaki et al. (95 cases): conservative 54.4%, endovascular 34.2%, indirect revascularization 7.6%, radiosurgery 2.5%, decompression 1.3% (yamaki2020thecurrentclinical pages 5-7).
From Hess et al. (84 patients): conservative 59.5%, embolization 28.6% (hess2022cerebralproliferativeangiopathy pages 3-4).
Targeted embolization is discussed as a selective strategy (e.g., fragile angioarchitecture or hemorrhagic foci) rather than curative obliteration, due to risk to intermingled parenchyma (yamaki2020thecurrentclinical pages 3-4, lasjaunias2008cerebralproliferativeangiopathy pages 1-2).
A systematic review focused on revascularization summarizes the rationale: revascularization is proposed to “disrupt regional hypoperfusion and interrupt the angiogenesis that defines CPA,” with early small-series results favorable but limited (hess2022cerebralproliferativeangiopathy pages 3-4).
Pediatric aggregation emphasizes indirect revascularization (e.g., pial synangiosis, burr-hole dural inversion) for symptomatic hypoperfusion, with reported durable collateralization and functional gains in illustrative follow-up (moskalik2026cerebralproliferativeangiopathy pages 1-3).
(a) Propranolol (beta-blocker) – 2023 case report A 2023 report describes long-term propranolol use for disabling headaches with reported angiographic “shrinkage of the vascular network” over 7 years, hypothesized via VEGF inhibition/antiproliferative effects; this remains anecdotal evidence (jongaliem2023useofbetablocker pages 2-4).
(b) Cilostazol (vasodilating agent) – 2024 case report A 2024 case report (Diffuse Proliferative Cerebral Angiopathy) reported rapid symptomatic improvement of aphasia after cilostazol in a steal-phenomenon phenotype confirmed by perfusion/acetazolamide challenge. The abstract states: “Within three days of treatment with cilostazol, the patient showed significant improvement in his aphasia.” (gautam2024thetreatmentof pages 1-2). Quantitative perfusion metrics (Tmax>4s and rCBF<38% volumes) improved after acetazolamide and over follow-up (gautam2024thetreatmentof pages 2-4).
A ClinicalTrials.gov search using CPA terms did not identify CPA-specific interventional trials in the retrieved results; the returned trials were unrelated (diabetes microangiopathy) (tool result; no CPA trial context IDs available for citation).
No primary-prevention interventions (vaccines, exposure avoidance) are described for CPA in the accessed literature. Prevention is best framed as: - Secondary prevention: avoiding misclassification as classic AVM and avoiding harmful aggressive AVM-directed eradication attempts (lasjaunias2008cerebralproliferativeangiopathy pages 1-2, singfer2023cerebralproliferativeangiopathy pages 1-4). - Tertiary prevention: seizure control, headache management, and individualized management of hypoperfusion/steal phenomena (jongaliem2023useofbetablocker pages 1-2, gautam2024thetreatmentof pages 2-4).
No natural disease analogs in non-human species were identified in the accessed literature.
No CPA-specific animal models, cellular models, or iPSC/organoid models were identified in the accessed literature.
The following table consolidates key quantitative and qualitative disease facts from the strongest available evidence (foundational cohort + systematic reviews + recent case reports).
| Domain | Key details (with numbers) | Main supporting sources (first author year; include URL) | Evidence type |
|---|---|---|---|
| Definition / classification | CPA is a rare cerebrovascular lesion distinct from classical brain AVM, characterized by a diffuse vascular network intermingled with normal brain parenchyma, large lesion size with relatively small shunting volume, and evidence of diffuse angiogenesis. In the original cohort, CPA represented 49/1434 AVM-database cases (3.4%). (lasjaunias2008cerebralproliferativeangiopathy pages 1-2, lasjaunias2008cerebralproliferativeangiopathy pages 2-4) | Lasjaunias 2008, https://doi.org/10.1161/STROKEAHA.107.493080; Yamaki 2020, https://doi.org/10.1007/s00701-020-04289-7 | Prospective databank cohort; systematic review |
| Demographics | Original series: mean age 22 years, 67% female. Systematic review of 95 cases: mean age 23 years, 60.0% female. Female predominance is roughly 2:1 in several summaries. (lasjaunias2008cerebralproliferativeangiopathy pages 1-2, yamaki2020thecurrentclinical pages 3-4, tiwari2020cerebralproliferativeangiopathy pages 3-4) | Lasjaunias 2008, https://doi.org/10.1161/STROKEAHA.107.493080; Yamaki 2020, https://doi.org/10.1007/s00701-020-04289-7; Tiwari 2020, https://doi.org/10.1055/s-0039-3401329 | Cohort; systematic review; case-based review |
| Presenting symptoms frequencies | Original cohort: seizures 45%, headaches 41%, TIAs/stroke-like symptoms 16%, hemorrhage 12%. Pooled review: headache 44.9%, seizures 37.1%, transient ischemic attacks 33.7%. Pediatric review (29 cases): focal deficits n=17, headache n=15, seizures n=6. (lasjaunias2008cerebralproliferativeangiopathy pages 2-4, yamaki2020thecurrentclinical pages 3-4, moskalik2026cerebralproliferativeangiopathy pages 1-3) | Lasjaunias 2008, https://doi.org/10.1161/STROKEAHA.107.493080; Yamaki 2020, https://doi.org/10.1007/s00701-020-04289-7; Moskalik 2026, https://doi.org/10.1007/s00381-026-07129-8 | Cohort; systematic reviews |
| Hemorrhage frequency / rebleed | Hemorrhagic presentation is uncommon: 12% (6/49) in the original cohort and 18.0% in the pooled review. However, once hemorrhage occurs, reported rebleeding is high: 67% in the original cohort / up to 67% in pooled literature; one death was reported in the original series. (lasjaunias2008cerebralproliferativeangiopathy pages 2-4, yamaki2020thecurrentclinical pages 3-4, lasjaunias2008cerebralproliferativeangiopathy pages 6-7) | Lasjaunias 2008, https://doi.org/10.1161/STROKEAHA.107.493080; Yamaki 2020, https://doi.org/10.1007/s00701-020-04289-7 | Cohort; systematic review |
| Key angiographic hallmarks | Typical DSA features: absence of dominant feeders; many small-caliber feeding arteries and draining veins; fuzzy/poorly circumscribed nidus; discrepancy between large nidus and small shunt volume; capillary angioectatic appearance 85.7% (43/49 in original cohort); perinidal angiogenesis ~46.6%-49%; transdural supply 59%-62.5%; proximal feeder stenosis 39%-43.1%; deep venous drainage 73%; no flow-related aneurysms. Nidus size often 3-6 cm (47.5%) or >6 cm (52.5%), with hemispheric extension 73%. (lasjaunias2008cerebralproliferativeangiopathy pages 4-6, yamaki2020thecurrentclinical pages 1-3, yamaki2020thecurrentclinical pages 3-4, lasjaunias2008cerebralproliferativeangiopathy pages 1-2) | Lasjaunias 2008, https://doi.org/10.1161/STROKEAHA.107.493080; Yamaki 2020, https://doi.org/10.1007/s00701-020-04289-7 | Cohort; systematic review |
| Key MRI / perfusion features | MRI/CT typically show a diffuse enhancing vascular network with normal brain parenchyma interspersed. Perfusion MRI shows increased CBV within the nidus, prolonged mean transit time, and widespread cortical/subcortical hypoperfusion remote from the nidus (increased TTP, decreased CBV in surrounding regions), supporting chronic oligemia/ischemia. DSA remains the diagnostic gold standard. (lasjaunias2008cerebralproliferativeangiopathy pages 6-7, tiwari2020cerebralproliferativeangiopathy pages 3-4, lasjaunias2008cerebralproliferativeangiopathy pages 1-2) | Lasjaunias 2008, https://doi.org/10.1161/STROKEAHA.107.493080; Tiwari 2020, https://doi.org/10.1055/s-0039-3401329; Singfer 2023, https://doi.org/10.5334/jbsr.3247 | Cohort; case-based review; case report |
| Management patterns and outcomes | Pooled review: conservative treatment 54.4%, endovascular treatment 34.2%, indirect revascularization 7.6%, radiosurgery 2.5%, decompression 1.3%. Outcomes at mean ~17 months: improved 50.7%, stable 40.2%, worsened 9.0%. In another review of 84 patients, conservative care was 59.5% and embolization 28.6%; among 78 with outcomes, conservative management led to spontaneous improvement in 39.7%, worsening in 46.1%, and no change in 12.8%. Original cohort follow-up totaled 145 patient-years (mean 3 years): after treatment, 16 improved, 6 were stable, 1 worsened. (yamaki2020thecurrentclinical pages 3-4, hess2022cerebralproliferativeangiopathy pages 3-4, lasjaunias2008cerebralproliferativeangiopathy pages 4-6) | Yamaki 2020, https://doi.org/10.1007/s00701-020-04289-7; Hess 2022, https://doi.org/10.1016/j.wneu.2022.05.096; Lasjaunias 2008, https://doi.org/10.1161/STROKEAHA.107.493080 | Systematic reviews; cohort |
| Selected emerging/individual treatment observations | Indirect cerebral revascularization has shown favorable outcomes in most small reported series and is used particularly for ischemic/hypoperfusion phenotypes. A 2023 case report described symptomatic and angiographic improvement over 7 years with propranolol, proposed as anti-angiogenic/VEGF-modulating therapy, but evidence remains anecdotal. (jongaliem2023useofbetablocker pages 1-2, moskalik2026cerebralproliferativeangiopathy pages 1-3) | Jong-A-Liem 2023, https://doi.org/10.1016/j.inat.2022.101663; Moskalik 2026, https://doi.org/10.1007/s00381-026-07129-8 | Case report; systematic review + illustrative case |
Table: This table summarizes the most clinically relevant facts about cerebral proliferative angiopathy, including how it is defined, how it presents, how it is diagnosed on imaging, and how it is managed. It is useful as a concise evidence-backed reference for distinguishing CPA from classical brain AVM.
References
(yamaki2020thecurrentclinical pages 1-3): Vitor Nagai Yamaki, Davi Jorge Fontoura Solla, João Paulo Mota Telles, Glaucia Lexy Jong Liem, Saul Almeida da Silva, José Guilherme Mendes Pereira Caldas, Manoel Jacobsen Teixeira, Eric Homero Albuquerque Paschoal, and Eberval Gadelha Figueiredo. The current clinical picture of cerebral proliferative angiopathy: systematic review. Acta Neurochirurgica, 162:1727-1733, Mar 2020. URL: https://doi.org/10.1007/s00701-020-04289-7, doi:10.1007/s00701-020-04289-7. This article has 25 citations and is from a peer-reviewed journal.
(tiwari2020cerebralproliferativeangiopathy pages 1-3): Sarbesh Tiwari, Pawan K. Garg, Pushpinder S. Khera, Santhosh Babu, Binit Sureka, and Taruna Yadav. Cerebral proliferative angiopathy: an uncommon and misdiagnosed entity. Journal of Clinical Interventional Radiology ISVIR, 4:107-110, Feb 2020. URL: https://doi.org/10.1055/s-0039-3401329, doi:10.1055/s-0039-3401329. This article has 7 citations.
(lasjaunias2008cerebralproliferativeangiopathy pages 1-2): Pierre L. Lasjaunias, Pierre Landrieu, Georges Rodesch, Hortensia Alvarez, Augustin Ozanne, Staffan Holmin, Wen-Yuan Zhao, Sasikhan Geibprasert, Dennis Ducreux, and Timo Krings. Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral avms. Stroke, 39:878-885, Mar 2008. URL: https://doi.org/10.1161/strokeaha.107.493080, doi:10.1161/strokeaha.107.493080. This article has 174 citations and is from a highest quality peer-reviewed journal.
(lasjaunias2008cerebralproliferativeangiopathy pages 2-4): Pierre L. Lasjaunias, Pierre Landrieu, Georges Rodesch, Hortensia Alvarez, Augustin Ozanne, Staffan Holmin, Wen-Yuan Zhao, Sasikhan Geibprasert, Dennis Ducreux, and Timo Krings. Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral avms. Stroke, 39:878-885, Mar 2008. URL: https://doi.org/10.1161/strokeaha.107.493080, doi:10.1161/strokeaha.107.493080. This article has 174 citations and is from a highest quality peer-reviewed journal.
(tiwari2020cerebralproliferativeangiopathy pages 3-4): Sarbesh Tiwari, Pawan K. Garg, Pushpinder S. Khera, Santhosh Babu, Binit Sureka, and Taruna Yadav. Cerebral proliferative angiopathy: an uncommon and misdiagnosed entity. Journal of Clinical Interventional Radiology ISVIR, 4:107-110, Feb 2020. URL: https://doi.org/10.1055/s-0039-3401329, doi:10.1055/s-0039-3401329. This article has 7 citations.
(lasjaunias2008cerebralproliferativeangiopathy pages 6-7): Pierre L. Lasjaunias, Pierre Landrieu, Georges Rodesch, Hortensia Alvarez, Augustin Ozanne, Staffan Holmin, Wen-Yuan Zhao, Sasikhan Geibprasert, Dennis Ducreux, and Timo Krings. Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral avms. Stroke, 39:878-885, Mar 2008. URL: https://doi.org/10.1161/strokeaha.107.493080, doi:10.1161/strokeaha.107.493080. This article has 174 citations and is from a highest quality peer-reviewed journal.
(yamaki2020thecurrentclinical pages 3-4): Vitor Nagai Yamaki, Davi Jorge Fontoura Solla, João Paulo Mota Telles, Glaucia Lexy Jong Liem, Saul Almeida da Silva, José Guilherme Mendes Pereira Caldas, Manoel Jacobsen Teixeira, Eric Homero Albuquerque Paschoal, and Eberval Gadelha Figueiredo. The current clinical picture of cerebral proliferative angiopathy: systematic review. Acta Neurochirurgica, 162:1727-1733, Mar 2020. URL: https://doi.org/10.1007/s00701-020-04289-7, doi:10.1007/s00701-020-04289-7. This article has 25 citations and is from a peer-reviewed journal.
(hess2022cerebralproliferativeangiopathy pages 3-4): Ryan M. Hess, Jeff F. Zhang, Justin M. Cappuzzo, Amade Bregy, and Elad I. Levy. Cerebral proliferative angiopathy presenting as subdural hematoma: a case report and systematic literature review. World Neurosurgery, 164:281-289, Aug 2022. URL: https://doi.org/10.1016/j.wneu.2022.05.096, doi:10.1016/j.wneu.2022.05.096. This article has 5 citations and is from a peer-reviewed journal.
(jongaliem2023useofbetablocker pages 1-2): Glaucia Suzanna Jong-A-Liem, Lillian dos Santos Carneiro, Fernando Mendes Paschoal Junior, Feres Eduardo Aparecido Chaddad Neto, Eberval Figueiredo Gadelha, E. Bor-Seng-Shu, and Eric Homero Albuquerque Paschoal. Use of beta-blocker in cerebral proliferative angiopathy: a case report. Interdisciplinary Neurosurgery, 31:101663, Mar 2023. URL: https://doi.org/10.1016/j.inat.2022.101663, doi:10.1016/j.inat.2022.101663. This article has 1 citations and is from a peer-reviewed journal.
(gautam2024thetreatmentof pages 2-4): Diwas Gautam, Daryl E Morrison, Michael T. Bounajem, Lubdha M. Shah, and Ramesh Grandhi. The treatment of symptomatic diffuse proliferative cerebral angiopathy with cilostazol: a case report. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.63387, doi:10.7759/cureus.63387. This article has 2 citations.
(jongaliem2023useofbetablocker pages 2-4): Glaucia Suzanna Jong-A-Liem, Lillian dos Santos Carneiro, Fernando Mendes Paschoal Junior, Feres Eduardo Aparecido Chaddad Neto, Eberval Figueiredo Gadelha, E. Bor-Seng-Shu, and Eric Homero Albuquerque Paschoal. Use of beta-blocker in cerebral proliferative angiopathy: a case report. Interdisciplinary Neurosurgery, 31:101663, Mar 2023. URL: https://doi.org/10.1016/j.inat.2022.101663, doi:10.1016/j.inat.2022.101663. This article has 1 citations and is from a peer-reviewed journal.
(moskalik2026cerebralproliferativeangiopathy pages 1-3): Anzhela D. Moskalik, Jonathan Mo, Monifa Sawyerr, Marike Zwienenberg, Branden Cord, and Julia D. Sharma. Cerebral proliferative angiopathy in pediatric patients: case-based review with an illustrative case. Child's Nervous System, Feb 2026. URL: https://doi.org/10.1007/s00381-026-07129-8, doi:10.1007/s00381-026-07129-8. This article has 0 citations.
(lasjaunias2008cerebralproliferativeangiopathy pages 4-6): Pierre L. Lasjaunias, Pierre Landrieu, Georges Rodesch, Hortensia Alvarez, Augustin Ozanne, Staffan Holmin, Wen-Yuan Zhao, Sasikhan Geibprasert, Dennis Ducreux, and Timo Krings. Cerebral proliferative angiopathy: clinical and angiographic description of an entity different from cerebral avms. Stroke, 39:878-885, Mar 2008. URL: https://doi.org/10.1161/strokeaha.107.493080, doi:10.1161/strokeaha.107.493080. This article has 174 citations and is from a highest quality peer-reviewed journal.
(singfer2023cerebralproliferativeangiopathy pages 1-4): Uri Singfer, Edward Baert, and Luc Defreyne. Cerebral proliferative angiopathy in a child, five years after an intraventricular hemorrhage and negative catheter angiography. Journal of the Belgian Society of Radiology, Aug 2023. URL: https://doi.org/10.5334/jbsr.3247, doi:10.5334/jbsr.3247. This article has 5 citations.
(gautam2024thetreatmentof pages 1-2): Diwas Gautam, Daryl E Morrison, Michael T. Bounajem, Lubdha M. Shah, and Ramesh Grandhi. The treatment of symptomatic diffuse proliferative cerebral angiopathy with cilostazol: a case report. Cureus, Jun 2024. URL: https://doi.org/10.7759/cureus.63387, doi:10.7759/cureus.63387. This article has 2 citations.
(singfer2023cerebralproliferativeangiopathy media 68b06269): Uri Singfer, Edward Baert, and Luc Defreyne. Cerebral proliferative angiopathy in a child, five years after an intraventricular hemorrhage and negative catheter angiography. Journal of the Belgian Society of Radiology, Aug 2023. URL: https://doi.org/10.5334/jbsr.3247, doi:10.5334/jbsr.3247. This article has 5 citations.
(singfer2023cerebralproliferativeangiopathy media 94c84d95): Uri Singfer, Edward Baert, and Luc Defreyne. Cerebral proliferative angiopathy in a child, five years after an intraventricular hemorrhage and negative catheter angiography. Journal of the Belgian Society of Radiology, Aug 2023. URL: https://doi.org/10.5334/jbsr.3247, doi:10.5334/jbsr.3247. This article has 5 citations.
(yamaki2020thecurrentclinical pages 5-7): Vitor Nagai Yamaki, Davi Jorge Fontoura Solla, João Paulo Mota Telles, Glaucia Lexy Jong Liem, Saul Almeida da Silva, José Guilherme Mendes Pereira Caldas, Manoel Jacobsen Teixeira, Eric Homero Albuquerque Paschoal, and Eberval Gadelha Figueiredo. The current clinical picture of cerebral proliferative angiopathy: systematic review. Acta Neurochirurgica, 162:1727-1733, Mar 2020. URL: https://doi.org/10.1007/s00701-020-04289-7, doi:10.1007/s00701-020-04289-7. This article has 25 citations and is from a peer-reviewed journal.